Evaluation of glycosylation for quality assurance of antibody pharmaceuticals by capillary electrophoresis.
The development of monoclonal antibody (mAb) pharmaceuticals has rapidly generated in this decade, and there are currently 23 FDA-approved mAb pharmaceuticals. Carbohydrate chains in mAb pharmaceuticals play important roles for the expression of their biological activities such as antibody-dependent cellular cytotoxicity, whereas the oligosaccharide profile is easily changed depending on the manufacturing conditions. Therefore, the evaluation of carbohydrate chains in detail is quite important for quality control in the development of mAb from early phases, but oligosaccharides in mAb have high heterogeneity and full characterization of oligosaccharide moiety in mAb has been a challenging target. Capillary electrophoresis (CE) is a powerful tool for the evaluation of glycan occupancy and oligosaccharide profile. This review focuses mainly on the application of CE to the analytical studies on glycosylation in mAb pharmaceuticals developed in our laboratory. The related techniques including the full-image microchip isoelectric focusing and the newly developed mass spectrometry technologies are also shown. The combination of the techniques described in this review will be a good guide for the evaluation of glycosylation for quality assurance of antibody pharmaceuticals by CE from the early stage of the development to the marketing stage.
Kamoda
Satoru
S
KIRIN Pharma Co. Ltd., Takasaki, Japan. skamoda@kirin.co.jp
Kakehi
Kazuaki
K
D000906:Antibodies / Q000737:chemistry*; D002240:Carbohydrate Sequence; D019075:Electrophoresis, Capillary / Q000379:methods*; D006031:Glycosylation; D013058:Mass Spectrometry; D008969:Molecular Sequence Data; D009844:Oligosaccharides / Q000737:chemistry; D004364:Pharmaceutical Preparations / Q000592:standards*; D011786:Quality Control
D000906:Antibodies; D009844:Oligosaccharides; D004364:Pharmaceutical Preparations